ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLCGlobeNewsWire • 04/15/24
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 04/08/24
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/05/24
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%Zacks Investment Research • 03/26/24
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To GainsSeeking Alpha • 03/13/24
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational UpdatesGlobeNewsWire • 03/11/24
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma ConferenceGlobeNewsWire • 03/06/24
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/05/24
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/01/24
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership SummitGlobeNewsWire • 02/14/24
Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's WhyZacks Investment Research • 02/08/24
Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 01/23/24
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming MilestonesGlobeNewsWire • 01/08/24
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination DevelopmentGlobeNewsWire • 12/11/23
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational UpdatesGlobeNewsWire • 11/06/23
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/02/23
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class ProfileGlobeNewsWire • 10/21/23
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023GlobeNewsWire • 10/17/23
Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 10/16/23